Clinical trials: Pulmonary Resistance
Pulmonary Disease
To Determine if a Lower Extremity Strengthening Program Improve Quadriceps Muscle Strength
The purpose of this study is to determine if a lower extremity strengthening program as part of pulmonary rehabilitation will improve quadriceps muscle strength, endurance and functional status as well as overall quality of life.
- Trial name
- Resistance (NCT01080703)
- Testing
- Exercise
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Chicago
Tuberculosis, Respiratory Tract Infections
Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis (ACT-TB Study)
This is a three-arm, open-label individually randomised controlled clinical trial investigating the benefits of the diagnostic use of broad-spectrum antimicrobials during the diagnostic process for tuberculosis (TB) and the risk…
- Conditions
- Tuberculosis, Respiratory Tract Infections, Pneumonia
- Trial name
- ACT-TB (NCT03545373)
- Testing
- Azithromycin, Amoxicillin
- Where
- Malawi
- Volunteers
- 1,583 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Ventilator Associated Pneumonia ( VAP), Mechanical Ventilation
Evaluation of the Role of Acetyl Cysteine in Ventilator Associated Pneumonia by Carbapenem Resistance Klebsiella
The aim of the study is to evaluate the role of addition of Acetyl cysteine in the management of VAP induced by carbapenem resistant klebsiella.
- Trial name
- NCT07097727
- Testing
- acetyl cysteine 600 mg, antibiotics and saline.
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Tanta University
Tuberculosis, Pulmonary
MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis
Estimate of clinical and microbiological efficacy of Levofloxacin (Tavanic) in combine therapy of MDR TB. Estimate of safety of Levofloxacin (Tavanic) in combine therapy of MDR TB.
- Trial name
- NCT00495339
- Testing
- Levofloxacin
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Sanofi
Ventilator Lung
Respiratory Mechanics Measurement of Ventilated Patients Through Low-frequency Oscillometry Technique
Respiratory failure has historically been one of the most important causes for admittance of patients to the critical care unit. This problem was the most important reason during the COVID-19 pandemic.
- Trial name
- NCT06483529
- Testing
- compliance measurement
- Where
- Belgium
- Volunteers
- 21 people
- Sponsor
- Universitair Ziekenhuis Brussel
Cystic Fibrosis
Exercise in People With Cystic Fibrosis on CFTR Modulator Therapy
Recently, the treatment of Cystic Fibrosis (CF) incorporated new modulators/enhancers of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).
- Trial name
- FIQMODE (NCT06322446)
- Testing
- Exercise
- Where
- Spain
- Volunteers
- 48 people
- Sponsor
- Universidad Politecnica de Madrid
Non-Small Cell Lung Cancer
EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study
The purpose of this study is to evaluate the optimal sequence of EGFR-inhibitors in lung cancer patients with EGFR-positive tumors not amenable for curative treatment.
- Trial name
- ERIS (NCT06486142)
- Testing
- Afatinib/Dacomitinib, Osimertinib
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Region Skane
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients
The goal of this observational study is to learn about the inspiratory flow rate capability in patients with pulmonary fibrosis (IPF or PPF) when using inhaler devices with different resistances.
- Trial name
- NCT07820254
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Lung Neoplasms
GILT Docetaxel - Non-Small Cell Lung Cancer
Primary Objective: To compare response rate between genotypic groups and control group. Secondary Objective: To determine the safety, time to treatment failure and survival in control and genotypic arms.
- Trial name
- NCT00174629
- Testing
- Docetaxel/DDP, docetaxel/gemcitabine
- Where
- 3 sites in Germany, Spain and 1 more
- Volunteers
- 449 people
- Sponsor
- Sanofi
COVID-19
Antimicrobial Resistance During the SARS-CoV-2 (COVID-19) Pandemic
Assess the incidence and rates of resistant pathogens prior to and during the COVID-19 pandemic.
- Trial name
- NCT06334731
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Methodist Health System
Rifampicin Resistant Tuberculosis, Drug-resistant Tuberculosis
Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial
The primary aim of this pragmatic trial is to determine the effectiveness of a Whole Genome Sequencing (WGS) Drug Sensitivity Testing (DST) strategy to guide individualised treatment of rifampicin resistant tuberculosis (RR-TB)…
- Conditions
- Rifampicin Resistant Tuberculosis, Drug-resistant Tuberculosis, Multidrug Resistant Tuberculosis, Pulmonary Tuberculoses
- Trial name
- SMARTT (NCT05017324)
- Testing
- WGS DST strategy
- Where
- South Africa
- Volunteers
- 248 people
- Sponsor
- Universiteit Antwerpen
Non Small Cell Lung Cancer
The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC)
Patients with advanced non-small cell lung cancer (NSCLC) who progress slowly after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors（EGFR-TKI）resistance.
- Trial name
- NCT03811054
- Testing
- Apatinib（250mg/d） combined with EGFR-TKI
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Chest Hospital
Lung Cancer
Analysis of the Microenvironment of Lung Cancer and Exploration of the Mechanism of Resistance to Immunotherapy
The investigators plan to conduct a multiomics analysis（such as, Genomics, proteomics, single cell RNA sequencing, space transcriptomics）of tumor tissue and blood, aiming at analyzing tumor heterogeneity, mapping the…
- Trial name
- NCT05636605
- Testing
- Multiomics analysis
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Adenocarcinoma of the Lung
Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
This is a randomized phase II study assessing the activity of single agent chemotherapy combined with nivolumab (Arm A) compared to single agent chemotherapy alone (Arm B) in squamous or non-squamous NSCLC subjects with primary…
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Adenocarcinoma of the Lung, Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT03041181
- Testing
- Docetaxel, Nivolumab, Gemcitabine
- Where
- 9 sites in United States
- Volunteers
- 3 people
- Sponsor
- Nasser Hanna, M.D.
Chronic Obstructive Pulmonary Disease
IMT in Ventilatory Muscle Metaboreflex in COPD
This research intends to evaluate if inspiratory muscle training (IMT) reduces inspiratory muscle metaboreflex through the decrease of calf vascular resistance and increase of calf blood flow in Chronic Obstructive Pulmonary…
- Trial name
- NCT01945398
- Testing
- Inspiratory Muscle Training
- Where
- Brazil
- Volunteers
- 13 people
- Sponsor
- Federal University of Rio Grande do Sul
Acute Respiratory Distress Syndrome After Cardiac Surgery Under Cardiopulmonary Bypass
Transpulmonary Gradient After Cardiac Surgery Under Cardiopulmonary Bypass
Get a better understanding of the pathophysiological processes of acute respiratory failure following cardiopulmonary bypass to initiate timely therapies targeted on a cell line.
- Trial name
- NCT01723930
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Non-small Cell Lung Cancer
Detection Cell Free DNA in Lung Cancer Patients
third generation of EGFR-TKIs is the newest target therapy for NSCLC. However, we did not known the specific mechanisms for those non-responders and patients grow resistance.Next generation sequencing is current the most…
- Trial name
- NCT02738593
- Where
- 2 sites in China
- Volunteers
- 124 people
- Sponsor
- Sun Yat-sen University
Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis
PRACTECAL-PKPD Sub Study
PRACTECAL-PKPD is an exploratory pharmacokinetic and pharmacodynamic sub-study investigating the relationship between the patients' exposure to anti- tuberculosis (TB) drugs in the TB-PRACTECAL trial investigational regimens and…
- Conditions
- Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis, Pulmonary Tuberculosis
- Trial name
- PRACTECAL-PKPD (NCT04081077)
- Testing
- Bedaquiline, Pretomanid, Moxifloxacin
- Where
- 5 sites in Belarus, South Africa
- Volunteers
- 240 people
- Sponsor
- Medecins Sans Frontieres, Netherlands
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
This phase Ib trial studies the side effects and best dose of osimertinib and navitoclax when given together and to see how well they work in treating patients with previously treated epidermal growth factor receptor…
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02520778
- Testing
- Navitoclax, Osimertinib
- Where
- 18 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer
Multiple Drug Resistance is the phenomena whereby cells become resistant to a variety of drugs with different mechanisms of action.
- Trial name
- NCT00437749
- Testing
- CBT-1
- Where
- United States
- Volunteers
- 214 people
- Sponsor
- CBA Research